Wang Chen, Wang Di, Pan Changqing, Zhang Jiazheng, Cheng Cheng, Zhai You, Yu Mingchen, Wang Zhiliang, Li Guanzhang, Zhang Wei
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China.
Beijing Neurosurgical Institute, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China.
Chin Neurosurg J. 2022 Dec 27;8(1):43. doi: 10.1186/s41016-022-00312-1.
Diagnosis and treatment of patients with glioblastoma (GBM) who are also diagnosed with primary non-central nervous system (CNS) tumors remain a challenge, yet little is known about the clinical characteristics and prognosis of these patients. The data presented here compared the clinical and pathological features between glioblastoma patients with or without primary non-CNS tumors, trying to further explore this complex situation.
Statistical analysis was based on the clinical and pathological data of 45 patients who were diagnosed with isocitrate dehydrogenase (IDH) wild-type glioblastoma accompanied by non-CNS tumors between January 2019 and February 2022 in Beijing Tiantan Hospital. Univariate COX proportional hazard regression model was used to determine risk factors for overall survival.
It turned out to be no significant difference in the overall survival (OS) of the 45 patients with IDH-wild-type GBM plus non-CNS tumors, compared with the 112 patients who were only diagnosed with IDH-wild-type GBM. However, there was a significant difference in OS of GBM patients with benign tumors compared to those with malignant tumors.
Implications for the non-central nervous system tumors on survival of glioblastomas were not found in this research. However, glioblastomas complicated with other malignant tumors still showed worse clinical outcomes.
胶质母细胞瘤（GBM）患者同时被诊断出患有原发性非中枢神经系统（CNS）肿瘤，其诊断和治疗仍然是一项挑战，然而对于这些患者的临床特征和预后却知之甚少。本文所呈现的数据比较了伴有或不伴有原发性非CNS肿瘤的胶质母细胞瘤患者的临床和病理特征，试图进一步探究这种复杂情况。
基于2019年1月至2022年2月在北京天坛医院诊断为异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤并伴有非CNS肿瘤的45例患者的临床和病理数据进行统计分析。采用单因素COX比例风险回归模型确定总生存的危险因素。
结果显示，45例IDH野生型GBM加非CNS肿瘤患者的总生存（OS）与仅诊断为IDH野生型GBM的112例患者相比无显著差异。然而，伴有良性肿瘤的GBM患者与伴有恶性肿瘤的患者相比，OS存在显著差异。
本研究未发现非中枢神经系统肿瘤对胶质母细胞瘤生存的影响。然而，胶质母细胞瘤合并其他恶性肿瘤仍显示出更差的临床结局。
